Eptinezumab for Childhood Migraine

"The trial is being conducted across 15 different sites, three of which are based in Ann Arbor, Pittsburgh and West Palm Beach. If you choose to take part it would be beneficial for you to opt for the closest location available in order to minimize travel needs."

"The risk-benefit analysis conducted by Power assigned a score of 1 to eptinezumab due to its Phase 1 status, indicating that there is limited information on the medication's safety and efficacy."

"This study is open to children aged 6-17, and there are 35 slots available for minors. For those over the age of 65, 121 positions remain unoccupied."

"At this juncture, the research team is not currently seeking new participants for this trial which was first made public on August 3rd 2020. However, there are 172 migrain studies and 7 eptinezumab trials that are presently recruiting patients."

"Research into eptinezumab began in 2020 and a Phase 1 trial, sponsored by H. Lundbeck A/S was completed that same year. Following the successful completion of this initial study which included 28 participants, approval for the drug's use in clinical trials was granted. Currently, there are 7 active studies involving 130 cities across 25 countries."

"Currently, 7 trials investigating the effects of eptinezumab are underway with 6 in Phase 3. Although most are situated in Valladolid and Île-de-France, there exist 291 locations running research on this medication's efficacy."

"According to the documents on clinicaltrials.gov, this trial is no longer enlisting participants. The study was first posted in August of 2020 and last updated in November of 2022; however, 179 other trials remain open for recruitment."

"This medical study is in search of 28 individuals aged 6-17 who have had a migraine diagnosis, as defined by the International Classification of Headache Disorders (ICHD)-3 criteria, for at least six months prior to screening. Furthermore, participants must be experiencing four or more migraines per month over the three preceding months before being admitted into the trial."